^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TSN084

    i
    Other names: TSN084
    Associations

    News

    Trials
    Company:
    Tyligand Bioscience
    Drug class:
    Multi-tyrosine kinase inhibitor
    Related drugs:
    Associations

    News

    Trials
    almost2years
    Phase I Study of TSN084 in Patients With Advanced Malignant Tumors. (clinicaltrials.gov)
    P1, N=74, Active, not recruiting, Tyligand Bioscience (Shanghai) Limited | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    TSN084
    almost2years
    TSN084 Treating Patients With Advanced Malignant Tumors (clinicaltrials.gov)
    P1, N=114, Recruiting, Tyligand Bioscience (Shanghai) Limited | Trial completion date: Mar 2026 --> Jun 2026 | Trial primary completion date: Sep 2025 --> Dec 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    TSN084
    2years
    TSN084 Treating Patients With Advanced Malignant Tumors (clinicaltrials.gov)
    P1, N=114, Recruiting, Tyligand Bioscience (Shanghai) Limited
    New P1 trial • Metastases
    |
    TSN084
    2years
    Phase I Study of TSN084 in Patients With Advanced Malignant Tumors. (clinicaltrials.gov)
    P1, N=74, Recruiting, Tyligand Bioscience (Shanghai) Limited | Trial completion date: Mar 2025 --> Jun 2025 | Trial primary completion date: Mar 2024 --> Mar 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    TSN084
    4years
    Phase I Study of TSN084 in Patients With Advanced Malignant Tumors. (clinicaltrials.gov)
    P1, N=74, Recruiting, Tyligand Bioscience (Shanghai) Limited
    New P1 trial
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • AXL (AXL Receptor Tyrosine Kinase) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    TSN084